

ANESTHESIOLOGY

Anesthesia and Developing Brains: Unanswered Questions and Proposed Paths Forward

Caleb Ing, M.D., M.S., David O. Warner, M.D., Lena S. Sun, M.D., Randall P. Flick, M.D., M.P.H., Andrew J. Davidson, M.B.B.S., M.D., F.A.N.Z.C.A., F.A.H.M.S., Laszlo Vutskits, M.D., Ph.D., Mary Ellen McCann, M.D., James O'Leary, M.D., David C. Bellinger, Ph.D., M.Sc., Virginia Rauh, Sc.D., Beverley A. Orser, M.D., Ph.D., F.R.C.P.C.C., Santhanam Suresh, M.D., Dean B. Andropoulos, M.D., M.H.C.M.

Anesthesiology 2022; 136:500–12

Questions regarding the safety of general anesthetic drugs in children emerged nearly 20 yr ago with the finding of neuronal apoptosis and functional deficits in rodents after exposure to these medications.¹ Over the course of the subsequent two decades, exposure to anesthetic agents during brain maturation has been found to consistently disrupt neurodevelopment in animal models.² In response, in December 2016, the U.S. Food and Drug Administration (Silver Spring, Maryland) issued a Drug Safety Communication regarding all commonly used anesthetics that bind to γ -aminobutyric acid and *N*-methyl-D-aspartate receptors.³ The Food and Drug Administration warning that “repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 yr old or in pregnant women during their third trimester may affect the development of children’s brains” was largely based on preclinical animal models and the limited clinical data available at the time.⁴ While preclinical data are convincing, the interpretation of the human data has been more complex, with some studies reporting an increased incidence of neurodevelopmental

ABSTRACT

Anesthetic agents disrupt neurodevelopment in animal models, but evidence in humans is mixed. The morphologic and behavioral changes observed across many species predicted that deficits should be seen in humans, but identifying a phenotype of injury in children has been challenging. It is increasingly clear that in children, a brief or single early anesthetic exposure is not associated with deficits in a range of neurodevelopmental outcomes including broad measures of intelligence. Deficits in other domains including behavior, however, are more consistently reported in humans and also reflect findings from nonhuman primates. The possibility that behavioral deficits are a phenotype, as well as the entire concept of anesthetic neurotoxicity in children, remains a source of intense debate. The purpose of this report is to describe consensus and disagreement among experts, summarize preclinical and clinical evidence, suggest pathways for future clinical research, and compare studies of anesthetic agents to other suspected neurotoxins.

(ANESTHESIOLOGY 2022; 136:500–12)

deficits in young children exposed to anesthetics and other studies finding no such differences.

Given the mixed results of the studies in children, the fundamental questions of the safety of commonly used anesthetics and whether this line of research inquiry should continue remains a source of intense debate. The purpose of this report is to provide expert consensus opinion regarding the state of the current preclinical and clinical evidence, the remaining questions, suggestions for future research, and comparisons to the evolution of research of other suspected neurotoxins, with the ultimate goal of ensuring that the millions of children who undergo procedures requiring anesthetic agents do so safely.^{5–7}

Preclinical Data from Animal Models and Translation to Humans

Animal studies convincingly show that general anesthetic medications induce a variety of morphofunctional alterations during brain development.² Although most preclinical studies have used rodent models, potentially more informative data are available from studies of nonhuman primates. The neonatal rhesus macaque is similar to human neonates with regard to physiology, pharmacology, early development, and behavior.⁸ In addition, unlike rodents,

This article is featured in “This Month in Anesthesiology,” page A1.

Submitted for publication June 10, 2021. Accepted for publication December 1, 2021. Published online first on January 11, 2022. From the Departments of Anesthesiology (C.I., L.S.S.) and Pediatrics (L.S.S.), Columbia University Vagelos College of Physicians and Surgeons, New York, New York; the Department of Anesthesiology (C.I.) and the Heilbrunn Department of Population and Family Health (V.R.), Mailman School of Public Health, Columbia University, New York, New York; the e Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, University Hospitals of Geneva, Geneva, Switzerland (L.V.); the Department of Anesthesiology, Critical Care and Pain Medicine (M.E.M.) and the Departments of Neurology and Psychiatry (D.C.B.), Harvard Medical School, Boston, Massachusetts; the Departments of Anesthesiology, Critical Care and Pain Medicine (M.E.M.) and Neurology and Psychiatry (D.C.B.), Boston Children’s Hospital, Boston, Massachusetts; the Department of Anesthesiology, Bon Secours Hospital, Cork, Ireland (J.O.); the Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (D.C.B.); the Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada (B.A.O.); the Departments of Anesthesiology and Pediatrics, Northwestern University, Chicago, Illinois (S.S.); and the Departments of Anesthesiology and Pediatrics, Texas Children’s Hospital, Houston, Texas (D.B.A.).

Copyright © 2022, the American Society of Anesthesiologists. All Rights Reserved. *Anesthesiology* 2022; 136:500–12. DOI: 10.1097/ALN.0000000000004116

neonatal rhesus macaques can be cared for using anesthetic equipment and techniques that are similar to those used for human neonates, ameliorating concerns that cognitive deficits in animal models are purely the result of physiologic instability rather than the effect of anesthetics.⁹

The Food and Drug Administration Drug Safety Communication was informed by preclinical nonhuman primate data, particularly regarding the duration of anesthesia and the risk of multiple anesthetic exposures. Neuronal apoptosis and behavioral changes were also seen in younger (5 to 6 days old) but not older nonhuman primates.¹⁰ However, given the lack of specific evaluations of nonhuman primates and humans at various ages between infancy and adulthood at the time of the release of the Drug Safety Communication in 2016, the 3-yr human age cutoff was a “best estimate” for a period of risk in humans based on the translational data for rapid synaptogenesis available at that time.^{11–13} Data from the nonhuman primate model have confirmed some of the *in vitro* effects of anesthetics on cultured neural tissue and *in vivo* effects observed in rodent models. Overall, these results have supported the concern from the Food and Drug Administration that γ -aminobutyric acid- and *N*-methyl-D-aspartate-binding anesthetics have adverse neurodegenerative effects that could compromise young children, including changes in behavioral, motor, and cognitive parameters.^{10,14–18}

Although these early nonhuman primate studies included only limited behavioral assessments, additional data published after the Food and Drug Administration warning was released further confirmed that behavioral changes (*i.e.*, anxiety, fear, and socialization behavior) characterize the nonhuman primate phenotype and also extended the period of vulnerability to at least postnatal day 40.^{19–22} Notably, in one study that evaluated both behavioral and cognitive abilities, alterations in spontaneous and provoked behavior were observed with no decrement in cognitive abilities such as working memory, executive function, and cognitive flexibility.²³

In attempting to translate preclinical data to humans, there are strengths and limitations to each animal model.¹⁴ Rodent models have found similar apoptotic injury patterns as those identified in nonhuman primates and can offer several advantages given the cost and ethical concerns of studies using nonhuman primates.²⁴ Recommendations on increasing the translational relevance of laboratory models alongside improving laboratory reporting standards have recently been published by the SmartTots Preclinical Working Group.¹⁴ Choosing appropriate outcomes that are relevant and translatable represents an ongoing challenge,² particularly in the absence of a clearly identifiable human phenotype. The lack of an obvious phenotype stems from the fact that the potential for pathology was first recognized in animals rather than the more typical sequence of developing an animal model in response to recognized human pathology. Additional caveats of extrapolation between

animal models and humans include physiologic monitoring issues, the developmental stage at the time of drug exposure, the length of exposure, and the absence of surgery and resulting inflammation. In the single study that included an assessment that is potentially directly translatable from studies of nonhuman primate to humans (the Operant Test Battery utilized by the Food and Drug Administration investigators), the detrimental effects observed in anesthetic-exposed rhesus macaques were not found in children²⁵; however, the duration of exposure to anesthetic drugs was much greater in the macaques.

Current State of the Clinical Evidence

Designing clinical studies based on outcomes assessed in animals has proven to be challenging for a variety of reasons.^{26,27} In particular, issues include the difficulty or impossibility of randomizing a child to not receive anesthesia for surgery, the long length of time required before neurodevelopmental deficits can be adequately assessed, and the challenges of identifying a phenotype of injury when any effect of anesthesia is likely to be at worst modest and therefore difficult to recognize in routine clinical assessments. In addition, since most clinical studies of anesthetic neurotoxicity are observational, they potentially have a multitude of potentially confounding factors, and appropriately accounting for these factors is also challenging.

Given the difficulty of performing randomized controlled trials or any prospective studies in this field, most studies are observational in nature and rely on data collected for other purposes. Among the available studies, there is significant heterogeneity in the types of surgical procedures, numbers of exposures, comparators, methods used to adjust for potential confounding (if any), and the outcomes examined. One systematic review published in 2017 found that even at that time, there were 67 studies evaluating neurodevelopmental outcomes after surgery and anesthesia that reported results from 73 different outcome measures.²⁸ By 2019, there were 90 studies published evaluating neurodevelopmental outcomes after surgery and anesthesia.²⁹

In most of these clinical studies, exposure to anesthesia and surgery is not consistently associated with deficits in clinically relevant outcomes including academic achievement,^{30–33} general intelligence,^{29,30,34–36} or memory and language.^{34–37} However, a more consistent association has been reported in subsets of studies that evaluated deficits in behavior,²⁹ executive function,^{29,36} social communication,³⁷ motor function,³⁷ and diagnoses of attention deficit hyperactivity disorder.³⁸ These deficits have been reported even after single exposures to anesthesia, which for most children is less than 1 h.^{6,39} That exposure-related differences are found in some outcomes but not others is plausible and may be particularly evident for outcomes that involve longer periods of observation in less structured settings such as parental reports of behavior and executive function.²⁹ In

the relatively few studies that have evaluated children with multiple exposures, adverse changes in behavior, executive function, motor function,³⁶ and the increased incidence of attention deficit hyperactivity disorder^{40,41} are more pronounced in multiply exposed compared to singly exposed children. However, because children who receive multiple or prolonged exposures also have a higher rate of comorbid conditions including prematurity, low birth weight,⁶ and higher American Society of Anesthesiologists status³⁹ compared with singly exposed children, addressing issues of unmeasured confounding and bias may be more complicated in studies of those children. As discussed in the following section, there are several potential confounding factors that complicate any causal interpretations of the relationships between anesthesia exposure and outcomes, including factors associated with both exposure and outcome. Although most observational studies employ various strategies to account for known differences in potentially relevant factors that differ between exposed and unexposed groups, there are still risks of unmeasured confounding that cannot be completely mitigated and should be considered when interpreting the study findings.

The ideal method to establish a causal relationship between an exposure and an outcome is by performing a randomized controlled trial. Unfortunately, because of the challenges in design and conduct, only one such study has been completed: the General Anesthesia or Awake-regional Anesthesia in Infancy (GAS) study, which randomized infants to receive either a brief sevoflurane anesthetic or an awake regional anesthetic^{34,42} and evaluated intelligence and a variety of secondary outcomes. In this equivalence trial, of all outcomes assessed, only the executive function secondary outcome was found to have both bounds of the 95% CI favoring evidence for a worse outcome with general anesthesia exposure.³⁴ While in the GAS study behavioral differences were found to be equivalent, in a meta-analysis that combined results from the GAS study with other studies using prospective outcome assessment (including the Pediatric Anesthesia NeuroDevelopment Assessment [PANDA] and Mayo Anesthesia Safety in Kids [MASK] studies),^{35,36} results from all included studies found general anesthetic-exposed children displaying consistent but small behavioral score differences but no differences in intelligence.²⁹ Of note, this phenotype consisting of deficits in behavioral function with no difference in measures of cognitive function after anesthetic exposure is similar to that reported in nonhuman primate studies.

Other Perioperative Factors that Could Affect Measured Outcomes

Other than a causal effect of anesthesia exposure, the most frequently proposed mechanisms to explain the observed associations between exposure to anesthesia and surgery and affected outcomes include perioperative physiologic disturbances, inflammation and psychologic stresses associated

with surgery, and the underlying conditions necessitating surgery (*i.e.* confounding by indication). The proposed relevant physiologic disturbances include hypoxia, hypocapnia, hypercapnia, and especially hypotension.⁴³ Blood pressures in anesthetized children are considerably lower than those found in nonanesthetized children,⁴⁴ and mild intraoperative decreases in cerebral oxygenation are common,⁴⁵ but a clear definition of intraoperative hypotension in pediatric patients does not exist.⁴⁶ The impact of lower blood pressures in children also remains unclear. While intraoperative hypotension has been associated with postoperative delirium in adults,^{47,48} a study evaluating multiply exposed children found no association between low intraoperative blood pressure values and neurodevelopmental outcomes.⁴⁹ Inflammation has also been hypothesized as a mechanism behind postoperative cognitive dysfunction in adults,⁵⁰ although the effects in children have not been examined. Although chronic illness or severe acute illness can cause psychologic distress that could impair development, even children with chronic significant illness can be surprisingly resilient in terms of cognitive development,⁵¹ and studies examining children undergoing common procedures find most children do not exhibit persistent postoperative psychologic distress.⁵² Perhaps the most frequently cited factor in the literature is confounding by indication, which refers to the fact that children requiring anesthesia may be more likely to have conditions that themselves are associated with adverse neurodevelopmental outcomes. While this is an important consideration, most children who require anesthesia do not have these conditions,⁶ and the results of some observational studies have not been sensitive to the exclusion of children undergoing major procedures such as cardiac surgery.³⁶ It is also not clear what conditions representing indications for surgery would consistently be associated with increased risk of adverse outcomes.⁵³ Indeed, surgery can improve conditions that cause adverse developmental outcomes such as attention deficit hyperactivity disorder⁵⁴ (*e.g.*, tonsillectomy and adenoidectomy normalizes measures of behavior and cognition in children with obstructive sleep apnea).

Consensus and Differences of Opinion in the Field

Biologically it is illogical to consider that morphologic changes that are consistently seen in the laboratory across so many species would not also occur humans. The challenge is to determine how these changes translate to clinically relevant human functional outcomes. Given the available preclinical and clinical evidence, there is still a broad, albeit not universal, consensus that based on the current evidence, there remains a possibility that anesthetic agents may cause a relevant long-term neurodevelopmental effect in children. As a result, there is also agreement that further research on this topic is justified. Some authors express concern that the challenges inherent in the design and conduct of these studies^{26,27} may preclude a definitive study or studies, while

others suggest that the appropriate studies are indeed possible using novel approaches. All authors of this report, however, agree that further research would provide improved evidence that would aid in clinical decision making (discussed below). Several potential research approaches have been suggested by the authors that may help generate the necessary evidence to answer the central question of whether anesthesia causes long-term neurodevelopmental problems in children (table 1).

What Evidence Would Be Required to Show that Exposure to General Anesthesia Causes Long-term Neurodevelopmental Deficits in Children?

Further Randomized Clinical Trials

Randomized controlled trials are often considered the gold standard for proving the causal effect of an exposure. Although these trials are very challenging to perform, particularly because children cannot be randomized to a placebo anesthetic for surgery, they may still be feasible and provide useful evidence. The Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanyl Anaesthesia in Young Children (T REX) trial, which evaluates children undergoing longer durations of anesthetic exposure, is currently underway.⁵⁵ The purpose of this trial is to evaluate a method to mitigate possible injury caused by anesthetic exposure and compares children exposed to low-dose sevoflurane (0.3 to 0.6%) in conjunction with remifentanyl and dexmedetomidine to a traditional higher dose sevoflurane anesthetic. The hypothesis is that remifentanyl and dexmedetomidine in conjunction with lower dose sevoflurane is either neuroprotective or less neurotoxic than higher dose sevoflurane alone. The primary outcome of interest in this study is intelligence as measured by full-scale intelligence quotient and is also examining other domains of neurodevelopment as secondary outcomes. If low-dose sevoflurane with remifentanyl and dexmedetomidine is found to be beneficial, that may imply a dose response in sevoflurane neurotoxicity and either the safety of a lower dose or a mitigating effect of dexmedetomidine and remifentanyl. A finding such as this would be important and could have immediate clinical applicability. However, if low- and high-dose sevoflurane are found to be equivalent, the interpretation would be more complicated because this could mean that these two dosing regimens could be either equally safe or equally toxic. Because there are limited data in animal models suggesting that a dexmedetomidine and remifentanyl anesthetic differs from sevoflurane on histologic and functional outcomes, the preclinical data may not help with the interpretation of such a result.

The T REX trial evaluates an important question using an international consortium and is currently the largest clinical trial evaluating anesthetic neurotoxicity in children. The limitations in such a study attest to the difficulty of

performing ethical and logistically feasible trials to evaluate the basic question of whether anesthetics cause measurable brain injury in children.²⁶ While further clinical trials would undoubtedly be helpful, at this time the optimal feasible study design is not obvious.

Observational Studies and Causal Theory

Uncommon events in large populations are difficult to study using traditional methods such as randomized controlled trials and prospective cohort studies. These situations are common in areas of public health such as environmental toxicology. In these settings, the application of causal theory can help establish the plausibility of a causal link between an exposure and an outcome. For example, a randomized controlled trial has not evaluated whether exposure to lead in children results in neurodevelopmental problems, but evidence synthesized across multiple observational and preclinical studies was convincing enough to result in policy changes to improve public health. Other examples in the pediatric literature include the association between prone sleep and sudden infant death syndrome and between aspirin use and Reye syndrome. The application of causal theory was proposed by Sir Austin Bradford Hill in 1965 in a seminal essay providing a framework of nine principles that could be used to guide the establishment of plausible causal relationships using observational data.⁵⁶ Although the Bradford Hill criteria remain one of the frequently cited frameworks for causal inference in epidemiologic studies, in recent years, calls have been made to modernize the criteria to take into account scientific and statistical advances.^{57,58} For example, one specific criterion that has been criticized suggests that large effect sizes are more likely to be causal than small effect sizes. It is now recognized that most causal associations tend to have relatively modest effect sizes, arguing against the strength of the association itself determining causality.⁵⁹ An in-depth application of a causal framework to anesthetic neurotoxicity can be performed⁶⁰ but is a complex and multi-faceted endeavor. A lesson learned when searching for associations between genotype and disease is the need to replicate studies, and with the accumulation of well designed clinical and preclinical studies, the utility of using causal frameworks to evaluate anesthetic neurotoxicity will likely increase. However, while these methods may aid in establishing causality, as discussed above, the challenge that remains is that in most observational studies, the anesthetic exposure cannot be completely isolated from the rest of the perioperative experience, inflammation, and comorbidities associated with surgery.

Use of Intermediate Outcomes or Biomarkers

Another challenge in the design of anesthesia-related neurotoxicity studies is the significant latency between exposure and assessment, as early assessment of cognition and behavior in young children may not be predictive of long-term

Table 1. Advantages and Disadvantages of Potential Research Approaches

| Approach | Advantages | Disadvantages |
|---|--|--|
| Further randomized controlled trials | Randomized controlled trials are the gold standard for proving causal effect of anesthetic exposure. | Randomized controlled trials are expensive and time consuming. Children cannot be randomized to no anesthetic, and what constitutes a “safe” anesthetic is unclear. A phenotype of injury and the ideal outcomes to evaluate are unclear. The optimal, feasible study design is not obvious. |
| Observational studies and causal theory | Randomized controlled trials may not be feasible in all situations. Causal theory is commonly applied to other areas such as environmental toxicity. | Observational studies are limited by the inability to distinguish effects of anesthesia from surgery and other perioperative factors, as well as issues with confounding by indication |
| Intermediate outcomes and biomarkers | Injury could be identified at an earlier stage. Objective pre- and postexposure testing could be performed. Endophenotypes could be identified. | Application of causal theory relies on well-designed observational studies. No consistent biomarkers have been identified. Any identified biomarker would need to be correlated to a long-term clinical outcome of interest. Intermediate outcomes and biomarkers would not be able to distinguish the effects of anesthesia from surgery and other perioperative factors. |
| Prenatal exposures | Translation between animal models and humans could be improved. Children may be more vulnerable to prenatal exposures. Less confounding by indication in the child as exposure is typically due to a condition in the mother rather than underlying conditions in the child. | The effects of anesthesia from uterine perfusion, inflammation, and other fetal stressors cannot be distinguished. A randomized controlled trial is unlikely to be able to randomize a mother to general anesthesia or spinal anesthesia. |
| Nonhuman primate studies | This is the animal model that is most similar to humans. This model can be used to evaluate questions that cannot be studied in humans. | Translation between humans and animal models is challenging. The one study that evaluated the same outcome in humans and nonhuman primates found differences in nonhuman primates but not children, although nonhuman primates had significantly longer exposures. |

function. Identifying suitable biomarkers associated with injury could be extremely valuable in (1) serving as intermediate outcomes that could facilitate clinical studies, (2) serving as “endophenotypes” of injury, and (3) providing insight into potential mechanisms of injury. Examples of biomarkers that have been explored in preclinical models in this context include brain imaging studies⁶¹ and serum-based assays.^{62,63}

Advantages and Challenges of Intermediate Outcomes

If the long-term neurodevelopmental effects of anesthesia are the ultimate outcome of interest, it can be argued that assessments cannot be made until adulthood because many neurodevelopmental domains may not fully mature until the late teens and early twenties. If an intermediate outcome such as a biomarker is found to be associated with long-term outcomes, injury could be identified at an earlier stage, reducing the time between exposure and assessment and thereby reducing the need for lengthy follow-up times. An objective biomarker could allow for the evaluation of children before and after exposure, which eliminates the confounding that occurs when comparing unexposed children with exposed children who may have higher rates of unrecognized underlying comorbid disease.

Endophenotypes

The identification of endophenotypes has also been raised as a method of identifying potential injury in children exposed to anesthesia. While a phenotype of a disorder is the associated collection of signs and symptoms that are immediately observable in that disorder, endophenotypes—“endo” meaning inside—has gained popularity with the development of advanced brain imaging and genetics. This concept applied to brain imaging has been used in environmental toxicology research as direct measures of the brain are in closer causal proximity to the genetic, environmental, and epigenetic determinants of clinical phenotypes than are cognition and behavior. In addition, the effects of putative genetic or environmental factors are often more robustly identified on brain imaging than with cognitive and behavioral testing. One relevant example is a study examining the relationship between prenatal exposure to polycyclic aromatic hydrocarbons (air pollution) and brain white matter, cognition, and behavior in children.⁶⁴ The authors found a dose-response relationship between prenatal exposure and specific regional reductions in white matter that mediated deficits in processing speed and attention deficit hyperactivity disorder severity, providing strong evidence for causality and potential insights into mechanism. These brain-based effects of prenatal exposure on white matter were much stronger and more robust in the presence of potential confounders than were the effects of exposure on cognition and behavior, presumably because many neural systems influence the performance on any

single cognitive or behavioral task, whereas the influence of prenatal exposure to neurotoxics on brain development can be more directly evaluated by imaging of the brain. Discoveries of these direct effects on the brain have allowed identification of previously unknown cognitive and behavioral consequences of the causal factors that had not been appreciated clinically⁶⁵ or that were suspected but not yet proven.⁶⁶ Therefore, identifying the neural systems that constitute a brain-based endophenotype may in turn allow investigators subsequently to identify more precisely which cognitive and behavioral functions early anesthesia exposure most robustly affects, if a specific pattern of imaging findings associated with anesthesia exposure is discovered. Determining causality, however, will continue to be a challenge as exposure to anesthesia remains linked to surgery and other related perioperative insults.

Mechanisms of Injury

Identifying biomarkers such as imaging abnormalities associated with exposure can also suggest mechanisms of injury. To again use the example of polycyclic aromatic hydrocarbons, these compounds have known cytotoxic effects that may help explain specific structural changes seen in children with higher exposures.⁶⁴ In the context of anesthetic neurotoxicity, the preclinical literature has suggested an abundance of potential mechanisms for neural injury and also the utility of imaging-based biomarkers with measurable differences 6 h to 1 week postexposure.⁶⁷ The application of biomarkers, particularly imaging modalities, may help examine some of the proposed preclinical mechanisms and aid translation between humans and animal models.

Although available imaging data are currently limited, there is some evidence that deficits in certain domains associated with anesthesia exposure may be associated with magnetic resonance imaging changes. Two extant studies compared available magnetic resonance imaging structural imaging in children exposed and unexposed to anesthesia,^{68,69} with another evaluating functional magnetic resonance imaging in nonhuman primates.⁷⁰ Although these studies have limitations, anesthetic exposure was found to be associated with imaging differences. Two ongoing National Institutes of Health–funded trials using prospectively collected magnetic resonance imaging images may provide further insight.

While biomarkers have the potential to allow for the development of new and more efficient study designs, identify unappreciated endophenotypes, and provide an improved mechanistic understanding of any injury, these methods also have limitations. The obvious limitation is that if these biomarker differences are identified, they still need to be correlated with a long-term outcome of interest, which is both a scientific and logistical challenge. Additionally, it may be difficult to determine whether a difference in a

biomarker is due to the anesthesia or other non-anesthetic-related effects of the perioperative exposure.

Prenatal Exposures

Many studies have evaluated neurodevelopmental outcomes after early childhood exposure. Despite the presence of the Food and Drug Administration Drug Safety Communication warning against anesthetic exposures in pregnant women,³ few clinical studies have evaluated children prenatally exposed to anesthetic agents outside the period of labor and delivery. In one small study of prenatal exposures,⁷¹ children were found to have behavioral deficits similar to those found in the prospective assessment of postnatally exposed children,²⁹ with the effect size for a single prenatal exposure similar to that reported after multiple postnatal exposures.³⁶ Evaluation of prenatal exposures may assess a neurodevelopmental period during which children are thought to be particularly vulnerable to the effects of anesthetics. In addition, children with prenatal exposures are not subject to the same confounding by indication as children with postnatal exposure as the reason for exposure typically lies with the mother rather than the fetus. In addition, the fetus would not have any psychologic impact from the surgical experience. Nonetheless, these studies present unique challenges in interpretation because of the effects of anesthesia and surgery on uterine perfusion, inflammation, maternal infection, and other fetal stressors. However, in one preclinical study, surgery was not found to result in additional cell death compared to anesthesia alone.⁷² Another limitation of this line of inquiry is that it is likely not amenable to a randomized controlled trial similar to the GAS study.³⁴ In pregnant women needing procedures when regional anesthesia is an option, a regional anesthetic is typically the standard of care, so it may not be ethical to randomize a woman to receive a general anesthetic.

Translation from Nonhuman Primate Models

While all animal models of anesthetic neurotoxicity have unique benefits, the nonhuman primate model is the most similar to humans and continues to be employed to address outstanding questions, including the critical window of vulnerability for the brain between birth and adulthood,²² whether a similar effect is seen in all ages within this vulnerable period, dosing threshold effects (*i.e.*, mean alveolar concentration \times time), and the effects of surgical trauma, inflammation, and pain on brain injury.² Additional questions that are currently being pursued include the optimal environment/socialization approaches to ameliorate brain injury and the effectiveness of various mitigating strategies, such as the use of alternative sedative drugs (*e.g.*, dexmedetomidine⁷³ and potential antidotes such as lithium, L-carnitine, and melatonin),^{74–76} and the impact of compounding physiologic factors including shifts in body temperature, alterations in blood pressure, and optimum

ventilation strategies.⁷⁷ Because data concerning the effect of prenatal anesthetic exposure on fetal and neonatal behavioral and cognitive development are still limited,⁷⁸ as are data concerning sex differences in response to anesthesia in the developing brain,⁷⁹ nonhuman primate models may help address these gaps in knowledge. Because many studies needed to answer critical questions will be difficult or impossible to conduct in humans, robust nonhuman primate data may be important in informing future research in humans.

Which Children Are the Most Vulnerable?

While the most pressing question is to determine whether early anesthesia exposure causes any long-term neurodevelopmental effects in children, additional important questions remain, including determining which children are most vulnerable. Significant numbers of children require multiple and lengthy exposures, and these children report deficits larger than those found in children after single exposures.^{36,40,41,80} Quantifying this increased risk is challenging, as these children tend to be more heterogeneous in terms of illness level and comorbidities than children who require a single exposure. The consequences of lengthy exposures have also not been well studied. Children with congenital anomalies who undergo surgery and anesthesia, particularly those with congenital cardiac anomalies, typically have lengthy exposures and have significant neurodevelopmental deficits.^{81,82} While these children may be more vulnerable to anesthetic agents, because they undergo major surgery and significant physiologic insult, isolating the effect of the anesthetic agent is difficult. Another potentially at-risk population is children of low socioeconomic status. In studies of neurotoxic substances such as pesticides, children of families of higher socioeconomic status show a reduced effect on IQ after exposure compared to children of families of lower socioeconomic status.⁸³ In children who were exposed to lead, compared to children of lower socioeconomic strata, those from higher socioeconomic strata required a higher level of lead exposure before seeing an effect on neurodevelopmental outcomes⁸⁴ and were able to more effectively recover from a toxic lead exposure.⁸⁵ While the MASK study did not find socioeconomic status to be a significant moderator,³⁶ children enrolled in some prospective studies such as the MASK and PANDA studies originated from significantly higher socioeconomic strata than the general population.^{35,36} Children enrolled in the GAS study, however, were found to have mothers who more closely reflected the maternal education level of the general population.⁴² While the Food and Drug Administration Drug Safety Communication defined the window of vulnerability as under 3 yr of age, as stated above, this threshold was an estimate based on translating the best preclinical data available. Since then, additional studies have identified similar associations between

anesthesia exposure and neurodevelopmental deficit at all ages under age 5 yr,^{38,86,87} and the critical window of vulnerability remains unclear.

Experience from Studies of Environmental Neurotoxins

Research on the neurotoxicity of environmental chemicals tends to evolve in a characteristic way. The initial studies tend to produce discrepant results due to a heterogeneity in design, population studied, exposure profiles, outcomes measured, and statistical approaches. Additional studies identify the key factors responsible for the discrepancies, and the public health community eventually arrives at a consensus about the magnitude of the risk in different populations. For some chemicals initially suspected of being neurotoxicants, subsequent research has suggested that the risk was modest, at best, at population levels of exposure. One example is ethyl mercury, a constituent of thimerosal, a vaccine preservative, that was considered by some to increase the risk of autism spectrum disorders in children.⁸⁸ This concern was shown to be baseless, and study of this chemical as a developmental neurotoxicant largely ended.⁸⁹ Lead, however, is an instructive example of a neurotoxicant on which the view on neurotoxicity has evolved dramatically as more data accumulated. In the 1980s, debate raged over whether “subclinical lead toxicity” existed or was solely the result of residual confounding by adversities associated with poverty. It was not until more than 30 yr later on the basis of many studies conducted in diverse settings that authoritative bodies such as the World Health Organization (Geneva, Switzerland) and Centers for Disease Control and Prevention (Atlanta, Georgia) agree that no level of lead exposure can be considered to be “safe.”^{90,91} Anyone who predicted in 1980 that this would be the eventual consensus would not have been taken at all seriously. Another line of inquiry that was important in drawing causal inferences about lead’s neurotoxicity at low levels of exposure was the concordance between the human epidemiologic evidence, which was based solely on observational studies, and the experimental animal studies, most notably using nonhuman primates.⁹²

Research focusing on the neurotoxic effects of early environmental exposure to pesticides and insecticides has followed a similar path as more data have accumulated but does provide some additional perspectives on risk assessment. For example, with respect to mechanism, the effects of exposure to organophosphate insecticides on brain development were initially assumed to derive from the same basic mechanism that produces acute systemic toxicity, in this case, inhibition of acetylcholinesterase and subsequent cholinergic hyperstimulation.⁹³ Subsequent evidence suggested additional noncholinergic mechanisms targeting events specific to the developing brain, and these events were likely to impair later performance on a range of cognitive and behavioral tasks.⁹⁴ This is worth noting because

in the case of pesticides and insecticides, noncholinergic mechanisms were found to dominate low-dose effects, while cholinesterase inhibition dominates toxic effects at higher doses. One caution suggested by this evolving research is that traditional methods of risk assessment based on classic monotonic dose–response relationships may not be appropriate for some neurotoxicants because of multiple mechanisms of action—mechanisms that may require elucidation through preclinical studies. In the case of some neurotoxic exposures, the timing of exposure during development likely determines the specificity of toxic effects at the cellular, neural systems, and neurobehavioral levels. The timing of assessment may also be important when assessing neurotoxins. More recently, with the advantage of extended longitudinal follow-up, accumulating evidence suggests longer-term effects of at least one insecticide on motor deficits and tremor in middle childhood—behavioral and neurologic domains that were not considered in the early studies assessing the safety of these chemical exposures.⁹⁵ Such experience argues for the consideration of new paradigms in the study of human health effects of early toxic exposures.⁶⁵

Conclusions

As more clinical studies have been published, several have found anesthetic exposure to be associated with deficits in some neurodevelopmental outcomes but not others. No association with broad measures of intelligence have been identified, but deficits in specific outcomes including behavioral function have been more consistently reported and reflect findings from studies of nonhuman primates. While these results may help identify a phenotype of injury after anesthesia exposure, new approaches to research will still be needed to determine whether a recognized phenotype is caused by the anesthetic medications or other factors related to surgery or the perioperative experience. While several pathways for clinical research have been proposed, whether any of the proposed studies can answer the basic question of: “Do anesthetic agents cause neurodevelopmental deficits in children?” is still being actively debated. When comparing the arc of research of anesthetic agents to that of other chemicals that have been evaluated as potential environmental neurotoxins, the body of research on anesthetics appears at present to be in the middle of this evolution, as investigators are still developing novel strategies for addressing the methodologic problems that inevitably beset human neurotoxicity studies. Whether the end of the story will be more similar to that for lead or for ethyl mercury is uncertain until further research is done. There is, however, consensus that further research evaluating the long-term neurodevelopmental effects of anesthetic medications is necessary and will be valuable for clinical decision-making when caring for children who need surgery and anesthesia.

Acknowledgments

The authors acknowledge Bradley Peterson, M.D. (Institute for the Developing Mind, Children’s Hospital, Los Angeles, California, and Division of Child and Adolescent Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, California), for helpful discussions regarding endophenotypes.

Competing Interests

This group of authors was assembled by SmartTots (San Francisco, California), a public-private partnership between the U.S. Food and Drug Administration (Silver Spring, Maryland) and the International Anesthesia Research Society (San Francisco, California) formed in 2009 to evaluate the possibility of adverse consequences of general anesthesia in young patients. No authors received any remuneration for their involvement in this article. However, any funding of the authors by SmartTots directly or indirectly or by either the Food and Drug Administration or the International Anesthesia Research Society is disclosed. While the International Anesthesia Research Society and Food and Drug Administration have shared interests and activities, they have no financial relationship, and each group is responsible for its own activities and resources. The International Anesthesia Research Society, however, does receive a National Institutes of Health (Bethesda, Maryland) grant from the Food and Drug Administration for specific research and administrative activities in support of SmartTots. Dr. Ing received a 1-yr SmartTots research grant in 2012 for the project “Anesthetic Exposure Duration and Effects on Cognitive Language Ability.” Dr. Warner and Dr. Flick received funding from the Food and Drug Administration between 2008 and 2011 (Food and Drug Administration SOL-08-SAFEKIDS CLIN 005–Project 5–Assessment of Long-term Cognitive Development following General Anesthesia as an Infant). Dr. Sun received funding from SmartTots between 2013 and 2016 to support the Pediatric Anesthesia and NeuroDevelopment Assessment (PANDA) Study and a conference grant to support the 2016 PANDA Symposium (New York, New York) and was the Medical Director of SmartTots from 2017 to 2018. She also received funding from the Food and Drug Administration between 2008 and 2011 (Food and Drug Administration SOL-08-SAFEKIDS Clin 004–Project 4) for the PANDA study from 2020 to 2022 (Food and Drug Administration 5U01 FD005936-05, subaward 417811G/UR FAO GR511088) for participation in the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, and from 2019 to 2023 (Food and Drug Administration contract 75F40119C10101 for BAA EETWP#31) for the project Neurodevelopmental Outcomes in Infants Receiving Opioid-Replacement Pharmacotherapy for Neonatal Opioid Withdrawal Syndrome. Dr. Sun and Dr. Davidson are also co-editor-in-chiefs of the Anesthesiology section of UpToDate, Riverwoods,

Illinois. Dr. McCann received funding from the Food and Drug Administration between 2008 and 2011 (Food and Drug Administration SOL-08-SAFEKIDS Clin 002-Project 2) for the General Anesthesia or Awake-Regional Anesthesia in Infancy (GAS) trial. Dr. Orser and Dr. Suresh serve on the Steering Committee for SmartTots without compensation or reimbursement. International Anesthesia Research Society policy specifically prohibits any payments to Trustees for work related to SmartTots. In addition, they serve as members of the International Anesthesia Research Society Board of Trustees and International Anesthesia Research Society Officers. As trustees, they receive reimbursement for travel expenses on behalf of International Anesthesia Research Society and honoraria for meetings on travel days. As officers, they receive a small stipend in addition to travel reimbursement. Dr. Andropoulos also serves on the Steering Committee for SmartTots without compensation or reimbursement, but his institution receives a partial salary reimbursement for his service as Medical Officer under the Food and Drug Administration grant. Dr. Davidson is an Executive Editor of *ANESTHESIOLOGY*, and Dr. Vutskits is an Editor of *ANESTHESIOLOGY*. Dr. Orser is also co-director of the Perioperative Brain Health Center (Toronto, Ontario, Canada; <http://www.perioperativebrainhealth.com>); is a named inventor on a Canadian patent (2,852,978) and two U.S. patents (9,517,265 and 10,981,954) describing new methods for preventing and treating delirium and persistent neurocognitive deficits after anesthesia and surgery; and also collaborates on clinical studies supported by in-kind software donations from Cogstate Ltd. (New Haven, Connecticut). The other authors declare no competing interests.

Research Support

Support was provided solely from institutional and/or departmental sources.

Correspondence

Address correspondence to Dr. Ing: Columbia University Vagelos College of Physicians and Surgeons and Mailman School of Public Health, 622 West 168th Street, BHN 4-440, New York, New York 10032. ci2119@cumc.columbia.edu. *ANESTHESIOLOGY*'s articles are made freely accessible to all readers on www.anesthesiology.org, for personal use only, 6 months from the cover date of the issue.

References

- Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF: Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. *J Neurosci* 2003; 23:876–82
- Vutskits L, Xie Z: Lasting impact of general anaesthesia on the brain: Mechanisms and relevance. *Nat Rev Neurosci* 2016; 17:705–17
- Food and Drug Administration Drug Safety Communication: FDA approves label changes for use of general anesthetic and sedation drugs in young children [4-27-2017]. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm>. Accessed November 1, 2017.
- Andropoulos DB, Greene MF: Anesthesia and developing brains: Implications of the FDA warning. *N Engl J Med* 2017; 376:905–7
- Rabbitts JA, Groenewald CB, Moriarty JP, Flick R: Epidemiology of ambulatory anesthesia for children in the United States: 2006 and 1996. *Anesth Analg* 2010; 111:1011–5
- Shi Y, Hu D, Rodgers EL, Katusic SK, Gleich SJ, Hanson AC, Schroeder DR, Flick RP, Warner DO: Epidemiology of general anesthesia prior to age 3 in a population-based birth cohort. *Paediatr Anaesth* 2018; 28:513–9
- Tzong KY, Han S, Roh A, Ing C: Epidemiology of pediatric surgical admissions in US children: Data from the HCUP kids inpatient database. *J Neurosurg Anesthesiol* 2012; 24:391–5
- Phillips KA, Bales KL, Capitanio JP, Conley A, Czoty PW, Hart BA, Hopkins WD, Hu SL, Miller LA, Nader MA, Nathanielsz PW, Rogers J, Shively CA, Voytko ML: Why primate models matter. *Am J Primatol* 2014; 76:801–27
- Martin LD, Dissen GA, McPike MJ, Brambrink AM: Effects of anesthesia with isoflurane, ketamine, or propofol on physiologic parameters in neonatal rhesus macaques (*Macaca mulatta*). *J Am Assoc Lab Anim Sci* 2014; 53:290–300
- Slikker W Jr, Zou X, Hotchkiss CE, Divine RL, Sadovova N, Twaddle NC, Doerge DR, Scallet AC, Patterson TA, Hanig JP, Paule MG, Wang C: Ketamine-induced neuronal cell death in the perinatal rhesus monkey. *Toxicol Sci* 2007; 98:145–58
- Casey BJ, Tottenham N, Liston C, Durston S: Imaging the developing brain: What have we learned about cognitive development? *Trends Cogn Sci* 2005; 9:104–10
- Dobbing J, Sands J: Comparative aspects of the brain growth spurt. *Early Hum Dev* 1979; 3:79–83
- Workman AD, Charvet CJ, Clancy B, Darlington RB, Finlay BL: Modeling transformations of neurodevelopmental sequences across mammalian species. *J Neurosci* 2013; 33:7368–83
- Chinn GA, Pearn ML, Vutskits L, Mintz CD, Loepeke AW, Lee JJ, Chen J, Bosnjak ZJ, Brambrink AM, Jevtovic-Todorovic V, Sun LS, Sall JW: Standards for preclinical research and publications in developmental anaesthetic neurotoxicity: Expert opinion statement from the SmartTots preclinical working group. *Br J Anaesth* 2020; 124:585–93
- Creeley CE, Dikranian KT, Dissen GA, Back SA, Olney JW, Brambrink AM: Isoflurane-induced apoptosis

- of neurons and oligodendrocytes in the fetal rhesus macaque brain. *ANESTHESIOLOGY* 2014; 120:626–38
16. Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, Martin LD, Dissen GA, Creeley CE, Olney JW: Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. *ANESTHESIOLOGY* 2012; 116:372–84
 17. Creeley C, Dikranian K, Dissen G, Martin L, Olney J, Brambrink A: Propofol-induced apoptosis of neurons and oligodendrocytes in fetal and neonatal rhesus macaque brain. *Br J Anaesth* 2013; 110(suppl 1):i29–38
 18. Paule MG, Li M, Allen RR, Liu F, Zou X, Hotchkiss C, Hanig JP, Patterson TA, Slikker W Jr, Wang C: Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. *Neurotoxicol Teratol* 2011; 33:220–30
 19. Alvarado MC, Murphy KL, Baxter MG: Visual recognition memory is impaired in rhesus monkeys repeatedly exposed to sevoflurane in infancy. *Br J Anaesth* 2017; 119:517–23
 20. Raper J, De Biasio JC, Murphy KL, Alvarado MC, Baxter MG: Persistent alteration in behavioural reactivity to a mild social stressor in rhesus monkeys repeatedly exposed to sevoflurane in infancy. *Br J Anaesth* 2018; 120:761–7
 21. Coleman K, Robertson ND, Dissen GA, Neuringer MD, Martin LD, Cuzon Carlson VC, Kroenke C, Fair D, Brambrink AM: Isoflurane anesthesia has long-term consequences on motor and behavioral development in infant rhesus macaques. *ANESTHESIOLOGY* 2017; 126:74–84
 22. Schenning KJ, Noguchi KK, Martin LD, Manzella FM, Cabrera OH, Dissen GA, Brambrink AM: Isoflurane exposure leads to apoptosis of neurons and oligodendrocytes in 20- and 40-day old rhesus macaques. *Neurotoxicol Teratol* 2017; 60:63–8
 23. Neudecker V, Perez-Zoghbi JF, Coleman K, Neuringer M, Robertson N, Bemis A, Glickman B, Schenning KJ, Fair DA, Martin LD, Dissen GA, Brambrink AM: Infant isoflurane exposure affects social behaviours, but does not impair specific cognitive domains in juvenile non-human primates. *Br J Anaesth* 2021; 126:486–99
 24. Goldstein PA: Nonhuman primates in anesthesia research: Have we reached the end of the road? *Anesth Analg* 2018; 126:2129–34
 25. Warner DO, Chelonis JJ, Paule MG, Frank RD, Lee M, Zaccariello MJ, Katusic SK, Schroeder DR, Hanson AC, Schulte PJ, Wilder RT, Sprung J, Flick RP: Performance on the Operant Test Battery in young children exposed to procedures requiring general anaesthesia: The MASK study. *Br J Anaesth* 2019; 122:470–9
 26. Davidson AJ, Becke K, de Graaff J, Giribaldi G, Habre W, Hansen T, Hunt RW, Ing C, Loepke A, McCann ME, Ormond GD, Pini Prato A, Salvo I, Sun L, Vutskits L, Walker S, Disma N: Anesthesia and the developing brain: A way forward for clinical research. *Paediatr Anaesth* 2015; 25:447–52
 27. Walkden GJ, Pickering AE, Gill H: Assessing long-term neurodevelopmental outcome following general anesthesia in early childhood: Challenges and opportunities. *Anesth Analg* 2019; 128:681–94
 28. Clausen NG, Kähler S, Hansen TG: Systematic review of the neurocognitive outcomes used in studies of paediatric anaesthesia neurotoxicity. *Br J Anaesth* 2018; 120:1255–73
 29. Ing C, Jackson WM, Zaccariello MJ, Goldberg TE, McCann ME, Grobler A, Davidson A, Sun L, Li G, Warner DO: Prospectively assessed neurodevelopmental outcomes in studies of anaesthetic neurotoxicity in children: A systematic review and meta-analysis. *Br J Anaesth* 2021; 126:433–44
 30. Glatz P, Sandin RH, Pedersen NL, Bonamy AK, Eriksson LI, Granath F: Association of anesthesia and surgery during childhood with long-term academic performance. *JAMA Pediatr* 2017; 171:e163470
 31. Graham MR, Brownell M, Chateau DG, Dragan RD, Burchill C, Fransoo RR: Neurodevelopmental assessment in kindergarten in children exposed to general anesthesia before the age of 4 years: A retrospective matched cohort study. *ANESTHESIOLOGY* 2016; 125:667–77
 32. O'Leary JD, Janus M, Duku E, Wijeyesundera DN, To T, Li P, Maynes JT, Crawford MW: A population-based study evaluating the association between surgery in early life and child development at primary school entry. *ANESTHESIOLOGY* 2016; 125:272–9
 33. Ing CH, DiMaggio CJ, Malacova E, Whitehouse AJ, Hegarty MK, Feng T, Brady JE, von Ungern-Sternberg BS, Davidson AJ, Wall MM, Wood AJ, Li G, Sun LS: Comparative analysis of outcome measures used in examining neurodevelopmental effects of early childhood anesthesia exposure. *ANESTHESIOLOGY* 2014; 120:1319–32
 34. McCann ME, de Graaff JC, Dorris L, Disma N, Withington D, Bell G, Grobler A, Stargatt R, Hunt RW, Sheppard SJ, Marmor J, Giribaldi G, Bellinger DC, Hartmann PL, Hardy P, Frawley G, Izzo F, von Ungern Sternberg BS, Lynn A, Wilton N, Mueller M, Polaner DM, Absalom AR, Szmuk P, Morton N, Berde C, Soriano S, Davidson AJ; GAS Consortium: Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): An international, multicentre, randomised, controlled equivalence trial. *Lancet* 2019; 393:664–77
 35. Sun LS, Li G, Miller TL, Salorio C, Byrne MW, Bellinger DC, Ing C, Park R, Radcliffe J, Hays SR, DiMaggio CJ, Cooper TJ, Rauh V, Maxwell LG, Youn A, McGowan FX: Association between a single general

- anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. *JAMA* 2016; 315:2312–20
36. Warner DO, Zaccariello MJ, Katusic SK, Schroeder DR, Hanson AC, Schulte PJ, Buenvenida SL, Gleich SJ, Wilder RT, Sprung J, Hu D, Voigt RG, Paule MG, Chelonis JJ, Flick RP: Neuropsychological and behavioral outcomes after exposure of young children to procedures requiring general anesthesia: The Mayo Anesthesia Safety in Kids (MASK) study. *ANESTHESIOLOGY* 2018; 129:89–105
 37. Walkden GJ, Gill H, Davies NM, Peters AE, Wright I, Pickering AE: Early childhood general anesthesia and neurodevelopmental outcomes in the Avon Longitudinal Study of Parents and Children Birth Cohort. *ANESTHESIOLOGY* 2020; 133:1007–20
 38. Ing C, Ma X, Sun M, Lu Y, Wall MM, Olfson M, Li G: Exposure to surgery and anesthesia in early childhood and subsequent use of attention deficit hyperactivity disorder medications. *Anesth Analg* 2020; 131:723–33
 39. Bartels DD, McCann ME, Davidson AJ, Polaner DM, Whitlock EL, Bateman BT: Estimating pediatric general anesthesia exposure: Quantifying duration and risk. *Paediatr Anaesth* 2018; 28:520–7
 40. Hu D, Flick RP, Zaccariello MJ, Colligan RC, Katusic SK, Schroeder DR, Hanson AC, Buenvenida SL, Gleich SJ, Wilder RT, Sprung J, Warner DO: Association between exposure of young children to procedures requiring general anesthesia and learning and behavioral outcomes in a population-based birth cohort. *ANESTHESIOLOGY* 2017; 127:227–40
 41. Sprung J, Flick RP, Katusic SK, Colligan RC, Barbaresi WJ, Bojanić K, Welch TL, Olson MD, Hanson AC, Schroeder DR, Wilder RT, Warner DO: Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia. *Mayo Clin Proc* 2012; 87:120–9
 42. Davidson AJ, Disma N, de Graaff JC, Withington DE, Dorris L, Bell G, Stargatt R, Bellinger DC, Schuster T, Arnup SJ, Hardy P, Hunt RW, Takagi MJ, Giribaldi G, Hartmann PL, Salvo I, Morton NS, von Ungern Sternberg BS, Locatelli BG, Wilton N, Lynn A, Thomas JJ, Polaner D, Bagshaw O, Szmuk P, Absalom AR, Frawley G, Berde C, Ormond GD, Marmor J, McCann ME; GAS Consortium: Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): An international multicentre, randomised controlled trial. *Lancet* 2016; 387:239–50
 43. McCann ME, Lee JK, Inder T: Beyond anesthesia toxicity: Anesthetic considerations to lessen the risk of neonatal neurological injury. *Anesth Analg* 2019; 129:1354–64
 44. de Graaff JC, Pasma W, van Buuren S, Duijghuisen JJ, Nafiu OO, Khetarpal S, van Klei WA: Reference values for noninvasive blood pressure in children during anesthesia: A multicentered retrospective observational cohort study. *ANESTHESIOLOGY* 2016; 125:904–13
 45. Olbrecht VA, Skowno J, Marchesini V, Ding L, Jiang Y, Ward CG, Yu G, Liu H, Schurink B, Vutskits L, de Graaff JC, McGowan FX Jr, von Ungern-Sternberg BS, Kurth CD, Davidson A: An international, multicenter, observational study of cerebral oxygenation during infant and neonatal anesthesia. *ANESTHESIOLOGY* 2018; 128:85–96
 46. Nafiu OO, Voepel-Lewis T, Morris M, Chimbira WT, Malviya S, Reynolds PI, Tremper KK: How do pediatric anesthesiologists define intraoperative hypotension? *Paediatr Anaesth* 2009; 19:1048–53
 47. Maheshwari K, Ahuja S, Khanna AK, Mao G, Perez-Protto S, Farag E, Turan A, Kurz A, Sessler DI: Association between perioperative hypotension and delirium in postoperative critically ill patients: A retrospective cohort analysis. *Anesth Analg* 2020; 130:636–43
 48. Wachtendorf LJ, Azimaraghi O, Santer P, Linhardt FC, Blank M, Suleiman A, Ahn C, Low YH, Teja B, Kendale SM, Schaefer MS, Houle TT, Pollard RJ, Subramaniam B, Eikermann M, Wongtangman K: Association between intraoperative arterial hypotension and postoperative delirium after noncardiac surgery: A retrospective multicenter cohort study. *Anesth Analg* 2021 [Epub ahead of print]
 49. Gleich SJ, Shi Y, Flick R, Zaccariello MJ, Schroeder DR, Hanson AC, Warner DO: Hypotension and adverse neurodevelopmental outcomes among children with multiple exposures to general anesthesia: Subanalysis of the Mayo Anesthesia Safety in Kids (MASK) study. *Paediatr Anaesth* 2021; 31:282–9
 50. Subramaniam S, Terrando N: Neuroinflammation and perioperative neurocognitive disorders. *Anesth Analg* 2019; 128:781–8
 51. Moser JJ, Veale PM, McAllister DL, Archer DP: A systematic review and quantitative analysis of neurocognitive outcomes in children with four chronic illnesses. *Paediatr Anaesth* 2013; 23:1084–96
 52. Kain ZN, Mayes LC, Caldwell-Andrews AA, Karas DE, McClain BC: Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. *Pediatrics* 2006; 118:651–8
 53. Roberts JE, Rosenfeld RM, Zeisel SA: Otitis media and speech and language: A meta-analysis of prospective studies. *Pediatrics* 2004; 113:e238–48
 54. Chervin RD, Dillon JE, Bassetti C, Ganoczy DA, Pituch KJ: Symptoms of sleep disorders, inattention, and hyperactivity in children. *Sleep* 1997; 20:1185–92
 55. Szmuk P, Andropoulos D, McGowan F, Brambrink A, Lee C, Lee KJ, McCann ME, Liu Y, Saynhalath R, Bong CL, Anderson BJ, Berde C, De Graaff JC, Disma N, Kurth D, Loepke A, Orser B, Sessler DI, Skowno JJ,

- von Ungern-Sternberg BS, Vutskits L, Davidson A: An open label pilot study of a dexmedetomidine-remifentanyl-caudal anesthetic for infant lower abdominal/lower extremity surgery: The T REX pilot study. *Paediatr Anaesth* 2019; 29:59–67
56. HILL AB: The environment and disease: Association or causation? *Proc R Soc Med* 1965; 58:295–300
 57. Cox LA Jr: Modernizing the Bradford Hill criteria for assessing causal relationships in observational data. *Crit Rev Toxicol* 2018; 48:682–712
 58. Fedak KM, Bernal A, Capshaw ZA, Gross S: Applying the Bradford Hill criteria in the 21st century: How data integration has changed causal inference in molecular epidemiology. *Emerg Themes Epidemiol* 2015; 12:14
 59. Ioannidis JP: Exposure-wide epidemiology: Revisiting Bradford Hill. *Stat Med* 2016; 35:1749–62
 60. Flick RP, Warner DO: A users' guide to interpreting observational studies of pediatric anesthetic neurotoxicity: The lessons of Sir Bradford Hill. *ANESTHESIOLOGY* 2012; 117:459–62
 61. Makaryus R, Lee H, Robinson J, Enikolopov G, Benveniste H: Noninvasive tracking of anesthesia neurotoxicity in the developing rodent brain. *ANESTHESIOLOGY* 2018; 129:118–30
 62. Wang C, Han X, Liu F, Patterson TA, Hanig JP, Paule MG, Slikker W Jr: Lipid profiling as an effective approach for identifying biomarkers/adverse events associated with pediatric anesthesia. *Toxicol Appl Pharmacol* 2018; 354:191–5
 63. Jiang J, Li S, Wang Y, Xiao X, Jin Y, Wang Y, Yang Z, Yan S, Li Y: Potential neurotoxicity of prenatal exposure to sevoflurane on offspring: Metabolomics investigation on neurodevelopment and underlying mechanism. *Int J Dev Neurosci* 2017; 62:46–53
 64. Peterson BS, Rauh VA, Bansal R, Hao X, Toth Z, Nati G, Walsh K, Miller RL, Arias F, Semanek D, Perera F: Effects of prenatal exposure to air pollutants (polycyclic aromatic hydrocarbons) on the development of brain white matter, cognition, and behavior in later childhood. *JAMA Psychiatry* 2015; 72:531–40
 65. Rauh VA, Margolis AE: Research review: Environmental exposures, neurodevelopment, and child mental health – New paradigms for the study of brain and behavioral effects. *J Child Psychol Psychiatry* 2016; 57:775–93
 66. Baker BH, Lugo-Candelas C, Wu H, Laue HE, Boivin A, Gillet V, Aw N, Rahman T, Lepage JF, Whittingstall K, Bellenger JP, Posner J, Takser L, Baccarelli AA: Association of prenatal acetaminophen exposure measured in meconium with risk of attention-deficit/hyperactivity disorder mediated by frontoparietal network brain connectivity. *JAMA Pediatr* 2020; 174:1073–81
 67. Zhang X, Liu S, Newport GD, Paule MG, Callicott R, Thompson J, Liu F, Patterson TA, Berridge MS, Apana SM, Brown CC, Maisha MP, Hanig JP, Slikker W Jr, Wang C: *In vivo* monitoring of sevoflurane-induced adverse effects in neonatal nonhuman primates using small-animal positron emission tomography. *ANESTHESIOLOGY* 2016; 125:133–46
 68. Backeljauw B, Holland SK, Altaye M, Loepke AW: Cognition and brain structure following early childhood surgery with anesthesia. *Pediatrics* 2015; 136:e1–12
 69. Taghon TA, Masunga AN, Small RH, Kashou NH: A comparison of functional magnetic resonance imaging findings in children with and without a history of early exposure to general anesthesia. *Paediatr Anaesth* 2015; 25:239–46
 70. Young JT, Vlasova RM, Howell BR, Knickmeyer RC, Morin E, Kuitouchoua KI, Lubach GR, Noel J, Hu X, Shi Y, Caudill G, Alexander AL, Niethammer M, Paule MG, Coe CL, Sanchez M, Styner M: General anaesthesia during infancy reduces white matter micro-organisation in developing rhesus monkeys. *Br J Anaesth* 2021; 126:845–53
 71. Ing C, Landau R, DeStephano D, Miles CH, von Ungern-Sternberg BS, Li G, Whitehouse AJO: Prenatal exposure to general anesthesia and childhood behavioral deficit. *Anesth Analg* 2021; 133:595–605
 72. Olutoye OA, Cruz SM, Akinkuotu AC, Sheikh F, Zamora IJ, Yu L, Adesina AM, Olutoye OO: Fetal surgery decreases anesthesia-induced neuroapoptosis in the mid-gestational fetal ovine brain. *Fetal Diagn Ther* 2019; 46:111–8
 73. Koo E, Oshodi T, Meschter C, Ebrahimnejad A, Dong G: Neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains. *J Toxicol Sci* 2014; 39:251–62
 74. Noguchi KK, Johnson SA, Kristich LE, Martin LD, Dissen GA, Olsen EA, Olney JW, Brambrink AM: Lithium protects against anaesthesia neurotoxicity in the infant primate brain. *Sci Rep* 2016; 6:22427
 75. Wang C, Liu F, Frisch-Daiello JL, Martin S, Patterson TA, Gu Q, Liu S, Paule MG, Hanig JP, Slikker W Jr, Crawford PA, Wang C, Han X: Lipidomics reveals a systemic energy deficient state that precedes neurotoxicity in neonatal monkeys after sevoflurane exposure. *Anal Chim Acta* 2018; 1037:87–96
 76. Yon JH, Carter LB, Reiter RJ, Jevtovic-Todorovic V: Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brain. *Neurobiol Dis* 2006; 21:522–30
 77. Ikonomidou C, Kirvassilis G, Swiney BS, Wang SH, Huffinan JN, Williams SL, Masuoka K, Capuano S III, Brunner KR, Crosno K, Simmons HS, Mejia AF, Turski CA, Brambrink A, Noguchi KK: Mild hypothermia ameliorates anesthesia toxicity in the neonatal macaque brain. *Neurobiol Dis* 2019; 130:104489
 78. Palanisamy A: Maternal anesthesia and fetal neurodevelopment. *Int J Obstet Anesth* 2012; 21:152–62

79. Cabrera OH, Gulvezan T, Symmes B, Quillinan N, Jevtovic-Todorovic V: Sex differences in neurodevelopmental abnormalities caused by early-life anaesthesia exposure: A narrative review. *Br J Anaesth* 2020; 124:e81–91
80. Wilder RT, Flick RP, Sprung J, Katusic SK, Barbaresi WJ, Mickelson C, Gleich SJ, Schroeder DR, Weaver AL, Warner DO: Early exposure to anesthesia and learning disabilities in a population-based birth cohort. *ANESTHESIOLOGY* 2009; 110:796–804
81. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, Mussatto KA, Uzark K, Goldberg CS, Johnson WH Jr, Li J, Smith SE, Bellinger DC, Mahle WT; American Heart Association Congenital Heart Defects Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Stroke Council: Neurodevelopmental outcomes in children with congenital heart disease: Evaluation and management: A scientific statement from the American Heart Association. *Circulation* 2012; 126:1143–72
82. Razzaghi H, Oster M, Reefhuis J: Long-term outcomes in children with congenital heart disease: National Health Interview Survey. *J Pediatr* 2015; 166:119–24
83. Stein LJ, Gunier RB, Harley K, Kogut K, Bradman A, Eskenazi B: Early childhood adversity potentiates the adverse association between prenatal organophosphate pesticide exposure and child IQ: The CHAMACOS cohort. *Neurotoxicology* 2016; 56:180–7
84. Bellinger D, Leviton A, Wateraux C, Needleman H, Rabinowitz M: Low-level lead exposure, social class, and infant development. *Neurotoxicol Teratol* 1988; 10:497–503
85. Bellinger D, Leviton A, Sloman J: Antecedents and correlates of improved cognitive performance in children exposed in utero to low levels of lead. *Environ Health Perspect* 1990; 89:5–11
86. Ing C, Sun M, Olfson M, DiMaggio CJ, Sun LS, Wall MM, Li G: Age at exposure to surgery and anesthesia in children and association with mental disorder diagnosis. *Anesth Analg* 2017; 125:1988–98
87. Shi Y, Dykhoff HJ, Guevara LRH, Sangaralingham LR, Schroeder DR, Flick RP, Zaccariello MJ, Warner DO: Moderators of the association between attention-deficit/hyperactivity disorder and exposure to anesthesia and surgery in children. *Br J Anaesth* 2021; 127:722–8
88. Bernard S, Enayati A, Redwood L, Roger H, Binstock T: Autism: A novel form of mercury poisoning. *Med Hypotheses* 2001; 56:462–71
89. Taylor LE, Swerdfeger AL, Eslick GD: Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies. *Vaccine* 2014; 32:3623–9
90. World Health Organization: Childhood Lead Poisoning, 2010. Available at: <https://www.who.int/ceh/publications/leadguidance.pdf>. Accessed October 12, 2021.
91. Advisory Committee on Childhood Lead Poisoning Prevention of the Centers for Disease Control and Prevention: Low level lead harms children: A renewed call for primary prevention. Available at: https://www.cdc.gov/nceh/lead/docs/final_document_030712.pdf. Accessed October 12, 2021.
92. U.S. EPA: Integrated Science Assessment (ISA) for Lead: U.S. Environmental Protection Agency, Washington, D.C., EPA/600/R-10/075F, 1998
93. Mileson BE, Chambers JE, Chen WL, Dettbarn W, Ehrich M, Eldefrawi AT, Gaylor DW, Hamernik K, Hodgson E, Karczmar AG, Padilla S, Pope CN, Richardson RJ, Saunders DR, Sheets LP, Sultatos LG, Wallace KB: Common mechanism of toxicity: A case study of organophosphorus pesticides. *Toxicol Sci* 1998; 41:8–20
94. Slotkin TA: Cholinergic systems in brain development and disruption by neurotoxicants: Nicotine, environmental tobacco smoke, organophosphates. *Toxicol Appl Pharmacol* 2004; 198:132–51
95. Rauh VA, Garcia WE, Whyatt RM, Horton MK, Barr DB, Louis ED: Prenatal exposure to the organophosphate pesticide chlorpyrifos and childhood tremor. *Neurotoxicology* 2015; 51:80–6